Filing Flows › Ligand Pharmaceuticals (LGND) › Next earnings date
Ligand Pharmaceuticals (LGND) earnings: beat the estimate
Ligand Pharmaceuticals (LGND) reported on Oct 29, 2026 and beat the EPS estimate: $2.67 against $2.33 (+14.7%). Revenue was $78.7M for Q3 2026, -32% year over year. It beat the EPS estimate in 80% of the quarters on record.
The last report
Ligand Pharmaceuticals reported revenue of $78.7M for the third quarter 2026 (-32% Y/Y), net loss $28.5M: Revenue from intangible royalty assets $47.2M, Ojemda $7.0M, Other $6.7M, Capvaxive $3.8M. How it makes money → · Every quarter →
Ligand Pharmaceuticals' latest quarter
Ligand Pharmaceuticals, Q3 2026: revenue $78.7M (-32% year over year), operating margin -20.0%, net loss $28.5M, operating cash flow −$27.6M. The chart follows the revenue to costs, profit and cash.
Questions
Did Ligand Pharmaceuticals beat earnings?
Ligand Pharmaceuticals (LGND) reported on Oct 29, 2026 and beat the EPS estimate: $2.67 against $2.33 (+14.7%).
When does LGND report earnings?
The next date is not set yet.
Does Ligand Pharmaceuticals usually beat earnings?
It beat the consensus EPS estimate in 80% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.